Director Stewart Brady purchased 30,000 shares of EOLS at $6.82, raising stake 51.2% amid 61.8% decline from 52-week high.
Stewart Brady, a Director, acquired 30,000 shares at $6.82 on August 15, 2025, substantially increasing his position from 58,629 shares to 88,629 shares (a 51.2% increase in holdings). The purchase occurred as the stock trades at $6.69, down 61.8% from its 52-week high of $17.49 and down 27.3% over the prior 30 days. Evolus is currently unprofitable with a net loss of $-17.1M against quarterly revenue of $69.4M, though the company posted annual revenue growth of 31.8% year-over-year. The transaction signals director accumulation during a steep drawdown, which may merit scrutiny given the stock's significant distance from recent highs and the company's ongoing losses, though strong top-line growth provides some operational counterweight.
Director David Moatazedi sold 127,905 shares (127.9K shares) for $1,283,195.27 in 2 transactions on 2025-06-13 and 2025-06-16
David Moatazedi sold 127.9K shares at a blended average price of $10.03 across two separate transactions, reducing his position by 26.0% from 492.8K to 364.9K shares. The stock is currently trading at $9.96, down 43.0% from its 52-week high of $17.49 and down 25.0% over the past 90 days, despite a recent 2.7% 30-day gain. His prior trades at EOLS show mixed timing: 2 of 5 prior sells were well-timed at the 90-day mark (stock declined after the sale), while 3 were poorly timed (stock rose). The company is unprofitable with a net loss of $18.9M in the latest quarter, though it posted 31.8% annual revenue growth, leaving unclear whether this sale reflects a strategic reassessment or portfolio rebalancing given the incomplete profitability picture.
Director Albert G White III purchases 20,000 shares at $9.45; holdings surge 65.8%; EOLS stock -43.6% from 52-week high.
Director Albert G White III purchased 20,000 shares of Evolus at $9.45, increasing his holdings to 50,378 shares—a 65.8% expansion of his pre-transaction position. The company is unprofitable with net income of $-18,892,000.00 against quarterly revenue of $68,522,000.00, though annual revenue growth reached +31.8%. The stock trades at $9.87 currently, down 43.6% from its 52-week high of $17.49, and has declined 26.4% over the past 90 days despite a modest +0.7% gain in the last 30 days. White's cross-ticker historical track record shows limited prior sells with neutral outcomes (avg 30d and 90d returns of -0.4%), providing minimal signal about his execution consistency. The combination of substantial position increase during a period of material price weakness and ongoing operating losses warrants investor attention to the company's path to profitability and the director's confidence rationale.
Evolus director Moatazedi sold 103.4K shares at $13.26 (−24.2% from high); stock down −10.4% in 30 days post-sale.
MOATAZEDI DAVID sold 103,376 shares of Evolus on 2025-03-18 at $13.26, reducing his holdings from 618,246 to 514,870 shares, a −16.7% reduction. The sale price is −24.2% from the 52-week high of $17.49, and the stock has fallen −10.4% in the 30 days since the transaction. Over his same-ticker history at EOLS (4 prior sales), 1 of 4 prior sells achieved negative 90-day returns, and the most recent transaction on 2024-03-19 resulted in a −21.9% 90-day decline. The company posted a net loss of $-19.2M against $61.1M quarterly revenue, indicating ongoing unprofitability despite +31.8% annual revenue growth. The confluence of a large share reduction at a depressed valuation, immediate post-sale weakness, and the company's negative earnings profile creates a signal worth monitoring, though the individual sale alone does not provide definitive directional conviction without additional context on open position composition or planned activity.
Add EOLS to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
